GlaxoSmithKline Debt to Equity Ratio Trend from 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC Debt to Equity Ratio is decreasing with stable movements from year to year. Debt to Equity Ratio is estimated to finish at 5.80 this year. For the period between 2010 and 2020, GlaxoSmithKline PLC, Debt to Equity Ratio quarterly trend regression had median of 5.80 and r-value of (0.19). GlaxoSmithKline PLC Operating Expenses is increasing as compared to previous years. The last year's value of Operating Expenses was reported at 14.93 Billion. The current Revenues is estimated to increase to about 33.9 B, while Cost of Revenue is estimated to decrease to under 11.4 B.

Search Historical Trends

 
Refresh
Check GlaxoSmithKline PLC financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 10 B, Consolidated Income of 4.6 B or Cost of Revenue of 11.4 B, as well as many exotic indicators such as Interest Coverage of 158, Long Term Debt to Equity of 2.7 or Calculated Tax Rate of 23.02. This can be a perfect complement to check GlaxoSmithKline PLC Valuation or Volatility. It can also complement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation with competitors.

GlaxoSmithKline Debt to Equity Ratio Marginal Breakdown

Showing smoothed Debt to Equity Ratio of GlaxoSmithKline PLC with missing and latest data points interpolated. Measures the ratio between Total Liabilities and Shareholders Equity.
ViewLast Reported 1.59 %10 Years Trend
Decreasing
Stable
 Debt to Equity Ratio 
      Timeline 

GlaxoSmithKline Debt to Equity Ratio Regression Statistics

Arithmetic Mean(60.81)
Coefficient Of Variation(391.64)
Mean Deviation 130.37
Median 5.80
Standard Deviation 238.15
Sample Variance 56,716
Range 825.97
R-Value(0.19)
Mean Square Error 60,799
R-Squared 0.035208
Significance 0.58
Slope(13.47)
Total Sum of Squares 567,155

GlaxoSmithKline Debt to Equity Ratio Over Time

2010  3.21 
2011  4.02 
2012  5.99 
2013  4.90 
2014  8.38 
2015  8.72 
2016  48.15 
2017 (777.82) 
2018  14.39 
2019  5.38 
2020  5.80 

About GlaxoSmithKline PLC Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Debt to Equity Ratio, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation with competitors. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page